The price hikes come even as the Trump administration pressures pharmaceutical companies to lower costs for patients and ...

The costs of at least 350 drugs in the U.S. are expected to rise in 2026, according to a new analysis, despite many of the ...

American pharma giant Pfizer ($PFE) leads the pack as pharmaceutical companies plan price increases for at least 350 branded ...

GSK (GSK) and other leading drugmakers plans to raise prices of as many as 350 medicines next year, with a median hike of ...

Pfizer's stock is down roughly 60% from its late 2021 highs, but the drug giant is working to innovate its way back into the ...

Pfizer faces another year of revenue decline in 2026, as Covid and loss-of-exclusivity headwinds weigh on top line growth.

This makes Pfizer a potentially cheap stock to buy while collecting a solid dividend. It's generated about $14 billion in ...

Pfizer (NYSE:PFE) and GlaxoSmithKline (NYSE:GSK) are among the top drugmakers planning price increases for hundreds of ...

A great dividend stock is one that's supported by a financially healthy, stable, and mature company with a proven commitment ...

Drugmakers plan to raise US prices on at least 350 branded medications including vaccines against COVID, RSV and shingles and ...

On December 16, Pfizer Inc. (NYSE:PFE) said the next few years are expected to be bumpy, starting in 2026. The company ...

Even as the Trump administration wants drugmakers to cut prices, the median industry raise will be about 4%, similar to last ...